In an ever-expanding market, TREG provides expert advice on how to navigate a rapidly evolving, complex, multidisease field with an increasing number of targeted therapies and novel pathways.

High-value clinical commentary

Since 2009, TREG has delivered high-value clinical commentary on established and novel therapies, the optimization of clinical trial design, treatment strategies and guidelines, drug safety and treatment outcomes, epidemiology, and disease burden.

A wealth of collective experience

TREG’s international faculty brings a wealth of experience in clinical practice as well as expertise in translational, clinical and epidemiological research, clinical trial design, and regulatory experience. This vast collective knowledge allows TREG to offer current, clinically relevant insights across a broad range of autoimmune and systemic inflammatory disorders, including rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, dermatomyositis and vasculitis, amongst others. Working in four distinct teams, TREG provides in-depth analysis on all relevant aspects of these diseases.

Mentoring the next generation of experts

TREG values and promotes the mentoring of the next generation of experts in the field. We hand-select new faculty members who bring their own expertise and provide a fresh perspective to the program.